The global control of the drug resistance tuberculosis has remained as major challenge. The present study was the first review study in the Middle East region in order to determine levels of Mycobacterium tuberculosis resistance to the first-line anti-TB drugs among both new and previously treated cases.
Background
Mycobacterium tuberculosis (M. tuberculosis) is considered as a major cause of morbidity and mortality in humankind and has remained as a significant increasing concern for global public health in the 21st century (1) (2) . Tuberculosis (TB) is an infectious disease caused by bacterium M. tuberculosis (tubercle bacillus). The tubercle bacillus has latently infected one-third of the global population (2) . According to the latest World Health Organization (WHO) estimation, there were 9 million new TB cases in 2013 with 1.5 million TB deaths in the world (3). Short course chemotherapy (SCC) of the first-line drugs, which is the treatment regimen recommended by WHO for new TB cases, is consisted of using 2 months of isoniazid, rifampicin, and pyrazinamide, plus a fourth drug (streptomycin or ethambutol), followed by 4 months of isoniazid and rifampicin (or alternatively, 6 months of isoniazid and ethambutol or thiacetazone) (4) . But recently, the prevalence rate of multidrug-resistant strains of M. tuberculosis (MDR-TB) resistant to at least isoniazid and rifampicin has provided difficulties for TB control strategies (5) . As the treatment, MDR strains require the use of second-line drugs that are much more toxic, expensive, and less effective than first-line drugs and need longer treatment period (about18.5months) (2, (6) (7) . Therefore, it is essential to perform drug susceptibility testing in order to detect and treat single drug resistant TB and prevent the emergence and spread of other forms of drug resistance (MDR, XDR and TDR) in new TB cases and also optimize the treatment (1, 7) .
TB is still one of the most common health problems in developing countries such as the Middle East countries. The Middle East is a region that covers S.W. Asia and N.E. Africa, stretching from the Mediterranean Sea to Pakistan and Afghanistan. Endemic countries with high burden of TB, Afghanistan and Pakistan, and high burden of MDR-TB, Iraq, are located in this region of the world (8) . The trends in the incidence of TB and the emergence of MDR-TB isolates in the Middle East countries are different. In 2011, the incidence of TB per 100000 populations in the Middle East countries including Iran, Kingdom of Saudi Arabia, Turkey, Egypt, Syria, Israel, Afghanistan, Pakistan, Iraq, Yemen, United Arab Emirates, Qatar, Oman, Lebanon, Kuwait, Jordan, and Bahrain were 21, 14, 20, 16, 17, 5.8, 189, 275, 45, 48, 1.8, 40, 11, 16, 24, 5.8, and 18, respectively (9) . In this year, the estimated MDR-TB cases among notified pulmonary TB cases in eastern Mediterranean countries was 17000, 7.8% for new TB cases and 21% for previously treated TB cases (9) . Our systematic review of the published literature with the estimations for incidence rate of mono and any drug resistance and then meta-analysis of obtained data provided better evidence than surveillance estimations of anti-TB drug resistance reported by the World Health Organization.
Objectives
To the extent of our knowledge, this is the first systematic review study on antibiotic resistance of M. tuberculosis in the Middle East region. The purpose of this paper was to evaluate the prevalence rate of anti-tuberculosis drug resistance to the first-line drugs both in new and previously treated TB cases and also assess some aspects related to antimicrobial resistance, including: 1) year and area of research, 2) number of TB positive patients (sex and mean age) and strains tested, 3) methods used for drug susceptibility testing (DST), and 4) site of disease by using a systematic review and meta-analysis.
Materials and Methods

Search strategy and evaluation criteria
In this systematic review, we performed the computer-assisted search by using the electronic databases of PubMed, Scopus, and Infect Epidemiol Med. 2017; Volume 3, Issue 1: 25- 35 26
Google Scholar in order to find published English language literature on antibiotic resistance in M. tuberculosis in the Middle East from 1981 to 2014. The authors used the medical terms including "antibiotic resistance", "M. tuberculosis", "Middle East", and "country of origin" for collecting a list of original research articles. Hand searching of reference lists was performed to identify any additional studies which might have been missed. Some limits were incorporated for the exclusion of irrelevant electronic search and repeated articles in databases. Inclusion criteria for the original articles to be included in our review after title, abstract, and full text review of articles, which should have been matched with our review, were consisted of: 1) being published in English language, 2) assessing drug susceptibility patterns of M. tuberculosis against first-line drugs (rifampicin, isoniazid, ethambutol, pyrazinamide and streptomycin), 3) investigating MDR-TB suspected patients. Exclusion criteria for the original articles to be excluded from our review were consisted of: 1) availability only with their native language, 2) availability only with their abstract, 3) investigating patients suspected to XDR and TDR-TB, 4) assessing drug susceptibility patterns of M. tuberculosis against second-line drugs, 5) containing data of the combined prevalence rate of drug resistance regardless of prior drug treatment, and 6) being review articles. Duplicate studies were discussed, and only the most recent reports were included in our systematic review.
Quality criteria
Based on eight main quality criteria proposed by Loney et al, relevant articles were investigated (Table 1) .
Characteristics of the target population
To extract the following data, all studies conducted in the Middle East region were assessed with regard to the target population characteristics, including: 1) their geographical area, 2) age, 3) sex, 4) type of patients (new/retreatment cases), 5) site of TB infection (pulmonary/extra-pulmonary specimens), and 6) clinical characteristics of patients.
Characteristics of sampling
To extract the following data, all of the studies conducted in the Middle East region were assessed with regard to the sampling characteristics, including: 1) sampling methods, 2) type of sample (pulmonary/extra-pulmonary specimens), 3) sample size/strains, and 4) number of patients.
Characteristics of antibiotic resistance of M. tuberculosis
To extract the following data, all of the studies conducted in the Middle East region were assessed with regard to the antibiotic resistance characteristics of M. tuberculosis, including: 1) the frequency of drug resistance to first-line anti-TB drugs (rifampicin, isoniazid, ethambutol, pyrazinamide, and streptomycin) both in new cases and previously treated TB cases, and 2) the frequency of MDR.
Laboratory diagnosis and antibiotic susceptibility testing methods
To extract the following data, all of the studies conducted in the Middle East region were assessed with regard to the laboratory diagnosis of M. tuberculosis and drug susceptibility testing (DST) methods, including 1) biochemical tests, and 2) common methods for the performance of M. tuberculosis drug susceptibility testing.
Definitions
In the present study, we defined mono drug resistance, any drug resistance, and MDR-TB as resistance to a single first-line drug, to one or more first-line drug, and to at least INH and RMP, respectively (8) . Also, patients with TB who had never received anti-TB drug or treated for less than 1 month were defined as new TB cases, and patients with previous history of receiving anti-TB treatment for at least 1 month were defined as previously treated TB cases (8) . In drug susceptibility testing methods, M. tuberculosis was considered as a resistant isolate, when bacterial growth was 1% or more on the medium containing antibiotic compared to antibiotic-free medium.
Statistical analysis
The frequency of drug resistance was expressed as percentage. We pooled data across studies using random effects model due to heterogeneity of the included studies. Heterogeneity was assessed by Cochran's Q test (p< 0.05 was considered statistically significant) and I 2 index. Meta-analyses were done for each country separately, and for different categorical variables, sub-group analyses were done to explore the effect of the variables on the resistance frequency. For publication bias evaluation, funnel plots were used. All analyses were done by CMA version 2.
Results
A total of 480 articles were collected on antibiotic resistance of M. tuberculosis in different countries of the Middle East region from 1981 to 2014. After screening, 82 papers were selected based on inclusion and exclusion criteria. In the present study, articles were selected from 17 Middle Eastern countries, there were 20 studies from Iran, 13 studies from Kingdom of Saudi Arabia, 17 studies from Turkey, 3 studies from Egypt, 1 study from Syria, 2 studies from Israel, 12 studies from Pakistan, 2 studies from Iraq, 1 study from Yemen, 2 studies from United Arab Emirates, 2 studies from Qatar, 2 studies from Oman, 3 studies from Lebanon, 1 study from Kuwait, and 1 study from Jordan. No study was found from Afghanistan and Bahrain. Out of 82 articles, 19 articles were excluded from the meta-analysis because they were duplicate publications of the same affiliation. Table 1 represents the year of research and the number of strains tested, the study location, the methods used to assess the resistance rate, the prevalence rate of drug-resistant TB, and other aspects related to patients, including the number of M. tuberculosis positive patients (new or previously treated TB cases), their age, sex, and site of disease. Table 2 shows the prevalence rate of mono drug resistance, any drug resistance, and MDR-TB both in new and previously treated TB patients in different countries of the Middle East. Based on the obtained results in Table 2 , countries with shared geographical borders such as Iran, Turkey, and Pakistan have similar drug resistance profile. Table 3 shows the overall antibiotic resistance pattern in the Middle East region. The number of the studies that contained data of mono, any, and multidrug resistance is presented in this table for both new and retreated TB cases. Also, for assessing heterogeneity of the studies included, we used the I 2 index and Cochran's Q test that show high heterogeneity between studies. Figure 2 is the funnel plot of the meta-analysis for detecting the presence of publication bias and assessing its impact on the analysis in both new and previously treated TB cases. The funnel plot shows some asymmetry which could be due to possible publication bias. Distribution of single, any, and MDR-TB among new TB cases in different countries of the Middle East are shown in Figure 3 . Drug resistance rate has not been evaluated completely in many countries such as Bahrain and Afghanistan, so it cannot fully be generalized to the country level and the Middle East region. Ultimately, Figure 4 presents the forest plot of the meta-analysis on mono drug resistance, any drug resistance, and MDR-TB in both new and previously treated TB patients. It has been arranged based on country, type of patients (new or previously treated), type of antibiotic resistance, event rate for each study as number (percent), and 95% confidence interval. Funnel plot of the meta-analysis on mono drug resistance, any drug resistance, and multidrug resistance in new and previously treated TB patients. Note slight asymmetry of the plot which could be due to possible publication bias. 
Discussion
Our study is the first comprehensive systematic review for the estimation of the prevalence rate of drug-resistant TB in the Middle East region. After reviewing the collected data, it was revealed that methods used for assessing the M. tuberculosis antibiotic susceptibility were different in countries of the Middle East (Table 1) . According to our data, it was revealed that the proportion method was constantly used to determine the antibiotic susceptibility in the Middle East region.
In the present study, the resistance of M. tuberculosis to a single first-line drug was detected in 14.7% (95% CI: 12.2% to 17.5%) of the new TB cases in the Middle East. The highest and the lowest mono drug resistance rate in new cases were detected in KSA (27%, 95% CI: 13.8% to 46.1%) and Iraq (2.6%, 95% CI: 0.4% to 16.5%), respectively. In previously treated TB cases in the Middle East, the resistance rate to a single first-line drug was found in 17.9% (95% CI: 14.6% to 21.7%) of the patients. Among the Middle Eastern countries, the highest prevalence rate of resistance to a single first-line drug was found in retreatment patients in Lebanon (25%, 95% CI: 1.9% to 85.3%), and the lowest rate was found in Yemen patients (7.5%, 95% CI: 2.9% to 18.4%). It seems that there is a strong correlation between mono drug resistance and the emergence of MDR-TB, particularly in isoniazid and rifampicin, which are the other forms of TB with more difficult treatment. So an urgent need to control the mono drug resistance in new TB cases and to treat these patients is felt.
The resistance to one or more first-line drugs was found in 20.8% (95% CI: 18% to 24%) of the new TB cases and 50.5% (95% CI: 43.2% to 57.8%) of the previously treated TB cases in the Middle East. Jordan had the highest prevalence rate of resistance to one or more first-line drug both in new and previously treated TB cases, 32.4%(95% CI: 24.4% to 41.7%) and 83.3% (95% CI: 65.7% to 92.9%), respectively. However, the lowest proportion in new and previously treated cases was detected in Oman (6%, 95% CI: 3.8% to 9.2%) and Iran (8.5%, 95% CI: 5.7% to 12.6%), respectively. For the new TB cases, our results are in agreement with other studies conducted in China (17.9%), Philippines (20.5%), India (21.3%), Norway (22·3%), Lithuania (24·2%), Peru (23·2%), and Northern Mariana Islands (22·2%,) (63) . But for previously treated TB cases, similar results have been shown in the studies conducted in Thailand (50.5%), Latvia (52·7%), Guatemala (54·8%), and Ethiopia (48.7%) (63) .
Drug-resistant TB is prevalent in different parts of the world, and according to the global reports, it was estimated that 3.5% of the new and 20.5% of the retreated TB patients had MDR-TB in 2013 (3). Compared with the global reports on TB in 2014, the prevalence rate of resistance to at least INH and RMP, MDR-TB, was found in 5% (95% CI: 3.7% to 6.8%) of the new TB cases and 26.6% of the retreatment cases (95% CI: 19.9% to 34.4%) in the Middle East, which shows increasing trend. High and low levels of resistance to at least INH and RMP among new cases were found in Israel (11.2%, 95% CI: 6.6% to 18.3%) and Qatar (0.45%, 95% CI: 0% to 2.5%), respectively. The MDR-TB rate in our study was high compared with the previous reports of WHO from the Middle East (9) . Also, the prevalence rate of MDR-TB in new and retreated cases in the Middle East was high in comparison with what has been reported from other parts of the world, for example, African region (1.9% and 9.4%), region of the Americas (2.1% and 11.5%), South-East Asia region (2.1% and 17.2%), and Western Pacific region (4.9% and 23.2%), and was low in comparison with what has been reported from European region (12.1% and 36.5%) for new and retreated cases, respectively (68) . In general, the prevalence rate of drug resistance is likely to change substantially during the course of the review (1981-2014). Therefore, because there are high MDR-TB burden countries in the Middle East and with regard to our results on the incidence rate of MDR-TB, in order to control the emergence of more MDR-TB and to reduce its impacts on public health, management of drug-susceptible or mono drug resistance TB is important.
Limitations
The main limitation of this review study which might have affected the meta-analysis results were consisted of: 1) not finding any study on M. tuberculosis resistance in Bahrain and Afghanistan, so it cannot completely represent the prevalence rate of drug resistance in the Middle East level, 2) the presence of articles with their native language, 3) exclusion of some articles from the study because of containing data from the combined prevalence rate of drug resistance (i.e. the prevalence rate of drug resistance among all cases of TB, regardless of prior drug treatment), 4) Immigration and mass gatherings because the prevalence rate of drug resistance of M. tuberculosis in many countries of the Middle East such as Iran, KSA, and Iraq is clearly influenced by immigrant workers and foreigners visiting Islamic rituals, 5) heterogeneity, we observed the great heterogeneity (high I 2 index) among the included studies for the pooled estimations of single drug resistance, any drug resistance, and MDR-TB in both new and previously treated cases, which could be due to differences in various countries, year and methods used between studies, and 6) evidence of possible systematic error (publication bias).
Conclusion
In sum, across 17 countries from the Middle East, the authors reported wide differences in the prevalence rate of mono, any, and multidrug resistance in both new and previously treated TB patients. The present systematic review showed high levels of drug-resistant TB, especially MDR-TB, which may be increasing in both groups of TB patients in the Middle East. Hence, in order to gain a more effective TB control, identifying individuals with TB signs and symptoms by new rapid diagnostic methods, performing drug susceptibility testing, detecting primary resistance to the first-line anti-TB drugs, providing effective treatment to prevent the emergence of other forms of drug resistance are needed. 
Abbreviations
Conflict of Interests
None declared. 
